Blue Owl Capital Co. III (NYSE:OBDE – Get Free Report) and Cybin (OTCMKTS:CLXPF – Get Free Report) are both small-cap finance companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.
Profitability
This table compares Blue Owl Capital Co. III and Cybin’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Blue Owl Capital Co. III | 63.33% | 13.62% | 6.78% |
Cybin | N/A | N/A | N/A |
Earnings & Valuation
This table compares Blue Owl Capital Co. III and Cybin’s gross revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Blue Owl Capital Co. III | $422.83 million | 4.30 | $271.96 million | $2.27 | 6.50 |
Cybin | $680,000.00 | 659.95 | -$24.42 million | ($0.24) | -12.58 |
Institutional and Insider Ownership
0.0% of Cybin shares are owned by institutional investors. 90.8% of Blue Owl Capital Co. III shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Blue Owl Capital Co. III and Cybin, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Blue Owl Capital Co. III | 0 | 0 | 1 | 0 | 3.00 |
Cybin | 0 | 0 | 0 | 0 | N/A |
Blue Owl Capital Co. III currently has a consensus price target of $16.00, suggesting a potential upside of 8.47%. Given Blue Owl Capital Co. III’s higher probable upside, research analysts clearly believe Blue Owl Capital Co. III is more favorable than Cybin.
Summary
Blue Owl Capital Co. III beats Cybin on 10 of the 12 factors compared between the two stocks.
About Blue Owl Capital Co. III
Blue Owl Capital Corporation is a specialty finance company focused on lending to U.S. middle-market companies. Blue Owl Capital Corporation is based in NEW YORK.
About Cybin
Cybin Inc., a life sciences company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Natures Journey. The Serenity Life segment engages in the research and development of pharmaceutical and nutraceutical psilocybin products. The Natures Journey segment focuses on non-psychedelic medical mushroom nutraceutical products. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.
Receive News & Ratings for Blue Owl Capital Co. III Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blue Owl Capital Co. III and related companies with MarketBeat.com's FREE daily email newsletter.